<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04244630</url>
  </required_header>
  <id_info>
    <org_study_id>19-094</org_study_id>
    <nct_id>NCT04244630</nct_id>
  </id_info>
  <brief_title>Mitochondrial Capacity Boost in ALS (MICABO-ALS) Trial</brief_title>
  <acronym>MICABO-ALS</acronym>
  <official_title>Mitochondrial Capacity Boost in ALS (MICABO-ALS) Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dallas VA Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dallas VA Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research is to investigate the validity of a previous clinical trial
      named EH301, which showed beneficial effects of anti-oxidant therapies in patients with
      amyotrophic lateral sclerosis (ALS). If validated by this study, providing over-the-counter
      anti-oxidants would be a simple, low risk, low-cost approach to significantly slow or stop
      the progression of ALS, for which currently no effective treatment exists. It is currently
      thought that oxidative stress is a major cause of ALS. The study investigators are therefore
      planning to expand the original scope of the previous trial by including anti-oxidants at
      high doses that were not previously used. All of these compounds are considered safe.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder that affects muscle
      function throughout the body. Weakness and muscle shrinkage begin either in the face, arm, or
      leg. A clinical ALS hallmark is rapidly progressive weight loss. Also, respiration is usually
      affected late in the disease, and death typically occurs as a consequence of respiratory
      failure. The median survival after disease onset is approximately 3-4 years.

      While there are now two FDA-approved agents for patients with ALS, there are no interventions
      that have had a meaningful impact on the natural course of this disease. Riluzole prolongs
      survival by up to 12 weeks. Edaravone improves some aspects of neurological function in a
      small subset of patients, but that was ineffective in clinical studies that included ALS
      patients at all stages of disease.

      Past failures to identify effective therapies reflect the complexity of ALS pathogenesis, in
      that no single therapeutic target has been identified. Thus, single agent or dual combination
      therapies are unlikely to succeed. Given the truly rapid and devastating nature of ALS and
      that there are no effective treatments for ALS, one can argue that it is critical to devise a
      different approach. Until the exact mechanisms that lead to ALS are identified, it is
      necessary to employ polytherapy which includes new agents that show promise.

      This study will lay further groundwork on methodology for performing more definite trials in
      ALS. The study of secondary biomarkers in ALS is significant because there are currently no
      molecular or biochemical biomarkers for assessing therapeutic efficacy of drug treatments in
      ALS clinical trials. By doing this study, the study investigators hope to learn that
      high-dose anti-oxidants would be a simple, low risk, low-cost approach to significantly slow
      or stop the progression of ALS, for which currently no effective treatment exists.
      Participation in this research will last about 13 months
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measurement of serum NfL</measure>
    <time_frame>12 months</time_frame>
    <description>The change in log serum NfL level from baseline to 12 months will be assessed using a linear mixed model and the differences in NfL level at 12 months from baseline assessed using a paired t-test.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measurement of functional decline in ALS</measure>
    <time_frame>12 months</time_frame>
    <description>Functional decline in ALS patients will be measured using the ALS Functional Rating Scale - Revised (ALSFRS-R), change will be measured from baseline to 12 months.
The ALSFRS-R is a quickly administered (five minutes) ordinal rating scale that assesses patients' capability and independence in 12 functional activities.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of serious adverse events and adverse events.</measure>
    <time_frame>12 months</time_frame>
    <description>The frequency of serious adverse events and adverse events will be summarized using frequency and percentages.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival analysis</measure>
    <time_frame>12 months</time_frame>
    <description>This is a robust measure of effect in this rapidly progressing terminal disease. Survival has been a standard outcome measure in past clinical trials.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in serum CK level from baseline to 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>CK levels will be measured in a clinical laboratory by colorimetric measurements. Analysis of serum CK levels will be conducted similar to serum NfL.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Amyotrophic Lateral Sclerosis (ALS)</condition>
  <arm_group>
    <arm_group_label>Antioxidants</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Eligible patients will receive over-the-counter anti-oxidants, namley CoQ10, vitamin E, NAc cysteine, and L-cystine at defined doses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Antioxidants</intervention_name>
    <description>Over-the-counter anti-oxidants, namley CoQ10, vitamin E, NAc cysteine, and L-cystine at defined doses</description>
    <arm_group_label>Antioxidants</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. A clinical diagnosis by a study investigator of laboratory-supported probable,
             probable, or definite ALS, according to a modified El Escorial criterion (Appendix 2).

          2. 21 to 80 years of age inclusive.

          3. If patients are taking riluzole for ALS, they must be on a stable dose for at least
             thirty days prior to the baseline visit.

          4. Willing and able to give signed informed consent that has been approved by the
             Institutional Review Board (IRB).

        Exclusion Criteria:

          1. Diagnosis of other neurodegenerative diseases (Parkinson disease, Alzheimer disease,
             etc.).

          2. Clinically significant history of unstable medical illness (unstable angina, advanced
             cancer, etc.) over the last 30 days.

          3. Infection with the human immunodeficiency virus (HIV)

          4. Limited mental capacity such that the patient cannot provide written informed consent
             or comply with evaluation procedures.

          5. History of recent alcohol or drug abuse or noncompliance with treatment or other
             experimental protocols. 6 Receipt of any investigational drug within the past 30 days.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olaf Stuve, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dallas VA Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rehana Hussain, M.Sc.</last_name>
    <phone>214-648-7244</phone>
    <email>rehana.hussain@utsouthwestern.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shirley OLeary, NP</last_name>
    <phone>214-857-4459</phone>
    <email>Shirley.OLeary@va.gov</email>
  </overall_contact_backup>
  <reference>
    <citation>Rowland LP, Shneider NA. Amyotrophic lateral sclerosis. N Engl J Med. 2001 May 31;344(22):1688-700. Review.</citation>
    <PMID>11386269</PMID>
  </reference>
  <reference>
    <citation>Akao Y, Maruyama W, Shimizu S, Yi H, Nakagawa Y, Shamoto-Nagai M, Youdim MB, Tsujimoto Y, Naoi M. Mitochondrial permeability transition mediates apoptosis induced by N-methyl(R)salsolinol, an endogenous neurotoxin, and is inhibited by Bcl-2 and rasagiline, N-propargyl-1(R)-aminoindan. J Neurochem. 2002 Aug;82(4):913-23.</citation>
    <PMID>12358797</PMID>
  </reference>
  <reference>
    <citation>O'Toole O, Traynor BJ, Brennan P, Sheehan C, Frost E, Corr B, Hardiman O. Epidemiology and clinical features of amyotrophic lateral sclerosis in Ireland between 1995 and 2004. J Neurol Neurosurg Psychiatry. 2008 Jan;79(1):30-2. Epub 2007 Jul 18.</citation>
    <PMID>17634215</PMID>
  </reference>
  <reference>
    <citation>Logroscino G, Traynor BJ, Hardiman O, Chiò A, Mitchell D, Swingler RJ, Millul A, Benn E, Beghi E; EURALS. Incidence of amyotrophic lateral sclerosis in Europe. J Neurol Neurosurg Psychiatry. 2010 Apr;81(4):385-90. doi: 10.1136/jnnp.2009.183525. Epub 2009 Aug 25.</citation>
    <PMID>19710046</PMID>
  </reference>
  <reference>
    <citation>Huisman MH, de Jong SW, van Doormaal PT, Weinreich SS, Schelhaas HJ, van der Kooi AJ, de Visser M, Veldink JH, van den Berg LH. Population based epidemiology of amyotrophic lateral sclerosis using capture-recapture methodology. J Neurol Neurosurg Psychiatry. 2011 Oct;82(10):1165-70. doi: 10.1136/jnnp.2011.244939. Epub 2011 May 27.</citation>
    <PMID>21622937</PMID>
  </reference>
  <reference>
    <citation>Wittie M, Nelson LM, Usher S, Ward K, Benatar M. Utility of capture-recapture methodology to assess completeness of amyotrophic lateral sclerosis case ascertainment. Neuroepidemiology. 2013;40(2):133-41. doi: 10.1159/000342156. Epub 2012 Oct 24.</citation>
    <PMID>23095852</PMID>
  </reference>
  <reference>
    <citation>van Es MA, Hardiman O, Chio A, Al-Chalabi A, Pasterkamp RJ, Veldink JH, van den Berg LH. Amyotrophic lateral sclerosis. Lancet. 2017 Nov 4;390(10107):2084-2098. doi: 10.1016/S0140-6736(17)31287-4. Epub 2017 May 25. Review.</citation>
    <PMID>28552366</PMID>
  </reference>
  <reference>
    <citation>Brooks BR. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial &quot;Clinical limits of amyotrophic lateral sclerosis&quot; workshop contributors. J Neurol Sci. 1994 Jul;124 Suppl:96-107.</citation>
    <PMID>7807156</PMID>
  </reference>
  <reference>
    <citation>Brooks BR, Miller RG, Swash M, Munsat TL; World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000 Dec;1(5):293-9. Review.</citation>
    <PMID>11464847</PMID>
  </reference>
  <reference>
    <citation>Gubbay SS, Kahana E, Zilber N, Cooper G, Pintov S, Leibowitz Y. Amyotrophic lateral sclerosis. A study of its presentation and prognosis. J Neurol. 1985;232(5):295-300.</citation>
    <PMID>4056836</PMID>
  </reference>
  <reference>
    <citation>Eisen A, Schulzer M, MacNeil M, Pant B, Mak E. Duration of amyotrophic lateral sclerosis is age dependent. Muscle Nerve. 1993 Jan;16(1):27-32.</citation>
    <PMID>8423829</PMID>
  </reference>
  <reference>
    <citation>Taylor JP, Brown RH Jr, Cleveland DW. Decoding ALS: from genes to mechanism. Nature. 2016 Nov 10;539(7628):197-206. doi: 10.1038/nature20413. Review.</citation>
    <PMID>27830784</PMID>
  </reference>
  <reference>
    <citation>Hokkanen SRK, Hunter S, Polvikoski TM, Keage HAD, Minett T, Matthews FE, Brayne C; MRC CFAS and CC75C Study Group. Hippocampal sclerosis, hippocampal neuron loss patterns and TDP-43 in the aged population. Brain Pathol. 2018 Jul;28(4):548-559. doi: 10.1111/bpa.12556. Epub 2017 Sep 25.</citation>
    <PMID>28833898</PMID>
  </reference>
  <reference>
    <citation>Keage HA, Hunter S, Matthews FE, Ince PG, Hodges J, Hokkanen SR, Highley JR, Dening T, Brayne C. TDP-43 pathology in the population: prevalence and associations with dementia and age. J Alzheimers Dis. 2014;42(2):641-50. doi: 10.3233/JAD-132351.</citation>
    <PMID>25170584</PMID>
  </reference>
  <reference>
    <citation>Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, Bruce J, Schuck T, Grossman M, Clark CM, McCluskey LF, Miller BL, Masliah E, Mackenzie IR, Feldman H, Feiden W, Kretzschmar HA, Trojanowski JQ, Lee VM. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006 Oct 6;314(5796):130-3.</citation>
    <PMID>17023659</PMID>
  </reference>
  <reference>
    <citation>Doble A. The pharmacology and mechanism of action of riluzole. Neurology. 1996 Dec;47(6 Suppl 4):S233-41. Review.</citation>
    <PMID>8959995</PMID>
  </reference>
  <reference>
    <citation>Cruz MP. Edaravone (Radicava): A Novel Neuroprotective Agent for the Treatment of Amyotrophic Lateral Sclerosis. P T. 2018 Jan;43(1):25-28.</citation>
    <PMID>29290672</PMID>
  </reference>
  <reference>
    <citation>de la Rubia JE, Drehmer E, Platero JL, Benlloch M, Caplliure-Llopis J, Villaron-Casales C, de Bernardo N, AlarcÓn J, Fuente C, Carrera S, Sancho D, GarcÍa-Pardo P, Pascual R, JuÁrez M, Cuerda-Ballester M, Forner A, Sancho-Castillo S, Barrios C, Obrador E, Marchio P, Salvador R, Holmes HE, Dellinger RW, Guarente L, Estrela JM. Efficacy and tolerability of EH301 for amyotrophic lateral sclerosis: a randomized, double-blind, placebo-controlled human pilot study. Amyotroph Lateral Scler Frontotemporal Degener. 2019 Feb;20(1-2):115-122. doi: 10.1080/21678421.2018.1536152. Epub 2019 Jan 22.</citation>
    <PMID>30668199</PMID>
  </reference>
  <reference>
    <citation>Yin TC, Britt JK, De Jesús-Cortés H, Lu Y, Genova RM, Khan MZ, Voorhees JR, Shao J, Katzman AC, Huntington PJ, Wassink C, McDaniel L, Newell EA, Dutca LM, Naidoo J, Cui H, Bassuk AG, Harper MM, McKnight SL, Ready JM, Pieper AA. P7C3 neuroprotective chemicals block axonal degeneration and preserve function after traumatic brain injury. Cell Rep. 2014 Sep 25;8(6):1731-1740. doi: 10.1016/j.celrep.2014.08.030. Epub 2014 Sep 15.</citation>
    <PMID>25220467</PMID>
  </reference>
  <reference>
    <citation>Pieper M, Scheffold C, Duwe S, Rossig C, Bisping G, Stelljes M, Tedder TF, Jurgens H, Berdel WE, Kienast J. Immunotherapy of B-cell malignancies with genetically engineered human CD8+ natural killer T cells. Leukemia. 2006 Apr;20(4):729-32.</citation>
    <PMID>16437143</PMID>
  </reference>
  <reference>
    <citation>Wang G, Han T, Nijhawan D, Theodoropoulos P, Naidoo J, Yadavalli S, Mirzaei H, Pieper AA, Ready JM, McKnight SL. P7C3 neuroprotective chemicals function by activating the rate-limiting enzyme in NAD salvage. Cell. 2014 Sep 11;158(6):1324-1334. doi: 10.1016/j.cell.2014.07.040.</citation>
    <PMID>25215490</PMID>
  </reference>
  <reference>
    <citation>Evers BM, Rodriguez-Navas C, Tesla RJ, Prange-Kiel J, Wasser CR, Yoo KS, McDonald J, Cenik B, Ravenscroft TA, Plattner F, Rademakers R, Yu G, White CL 3rd, Herz J. Lipidomic and Transcriptomic Basis of Lysosomal Dysfunction in Progranulin Deficiency. Cell Rep. 2017 Sep 12;20(11):2565-2574. doi: 10.1016/j.celrep.2017.08.056.</citation>
    <PMID>28903038</PMID>
  </reference>
  <reference>
    <citation>Radford RA, Morsch M, Rayner SL, Cole NJ, Pountney DL, Chung RS. The established and emerging roles of astrocytes and microglia in amyotrophic lateral sclerosis and frontotemporal dementia. Front Cell Neurosci. 2015 Oct 27;9:414. doi: 10.3389/fncel.2015.00414. eCollection 2015. Review.</citation>
    <PMID>26578880</PMID>
  </reference>
  <reference>
    <citation>Desai VG, Herman EH, Moland CL, Branham WS, Lewis SM, Davis KJ, George NI, Lee T, Kerr S, Fuscoe JC. Development of doxorubicin-induced chronic cardiotoxicity in the B6C3F1 mouse model. Toxicol Appl Pharmacol. 2013 Jan 1;266(1):109-21. doi: 10.1016/j.taap.2012.10.025. Epub 2012 Nov 7.</citation>
    <PMID>23142469</PMID>
  </reference>
  <reference>
    <citation>Gaiottino J, Norgren N, Dobson R, Topping J, Nissim A, Malaspina A, Bestwick JP, Monsch AU, Regeniter A, Lindberg RL, Kappos L, Leppert D, Petzold A, Giovannoni G, Kuhle J. Increased neurofilament light chain blood levels in neurodegenerative neurological diseases. PLoS One. 2013 Sep 20;8(9):e75091. doi: 10.1371/journal.pone.0075091. eCollection 2013.</citation>
    <PMID>24073237</PMID>
  </reference>
  <reference>
    <citation>Lu CH, Macdonald-Wallis C, Gray E, Pearce N, Petzold A, Norgren N, Giovannoni G, Fratta P, Sidle K, Fish M, Orrell R, Howard R, Talbot K, Greensmith L, Kuhle J, Turner MR, Malaspina A. Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis. Neurology. 2015 Jun 2;84(22):2247-57. doi: 10.1212/WNL.0000000000001642. Epub 2015 May 1. Erratum in: Neurology. 2015 Sep 8;85(10):921.</citation>
    <PMID>25934855</PMID>
  </reference>
  <reference>
    <citation>Benatar M, Wuu J, Andersen PM, Lombardi V, Malaspina A. Neurofilament light: A candidate biomarker of presymptomatic amyotrophic lateral sclerosis and phenoconversion. Ann Neurol. 2018 Jul;84(1):130-139. doi: 10.1002/ana.25276. Epub 2018 Aug 16.</citation>
    <PMID>30014505</PMID>
  </reference>
  <reference>
    <citation>Verde F, Steinacker P, Weishaupt JH, Kassubek J, Oeckl P, Halbgebauer S, Tumani H, von Arnim CAF, Dorst J, Feneberg E, Mayer B, Müller HP, Gorges M, Rosenbohm A, Volk AE, Silani V, Ludolph AC, Otto M. Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2019 Feb;90(2):157-164. doi: 10.1136/jnnp-2018-318704. Epub 2018 Oct 11.</citation>
    <PMID>30309882</PMID>
  </reference>
  <reference>
    <citation>Thouvenot E, Demattei C, Lehmann S, Maceski-Maleska A, Hirtz C, Juntas-Morales R, Pageot N, Esselin F, Alphandéry S, Vincent T, Camu W. Serum neurofilament light chain at time of diagnosis is an independent prognostic factor of survival in amyotrophic lateral sclerosis. Eur J Neurol. 2020 Feb;27(2):251-257. doi: 10.1111/ene.14063. Epub 2019 Sep 18.</citation>
    <PMID>31437330</PMID>
  </reference>
  <reference>
    <citation>Feneberg E, Oeckl P, Steinacker P, Verde F, Barro C, Van Damme P, Gray E, Grosskreutz J, Jardel C, Kuhle J, Koerner S, Lamari F, Amador MDM, Mayer B, Morelli C, Muckova P, Petri S, Poesen K, Raaphorst J, Salachas F, Silani V, Stubendorff B, Turner MR, Verbeek MM, Weishaupt JH, Weydt P, Ludolph AC, Otto M. Multicenter evaluation of neurofilaments in early symptom onset amyotrophic lateral sclerosis. Neurology. 2018 Jan 2;90(1):e22-e30. doi: 10.1212/WNL.0000000000004761. Epub 2017 Dec 6.</citation>
    <PMID>29212830</PMID>
  </reference>
  <reference>
    <citation>Kaufmann P, Levy G, Montes J, Buchsbaum R, Barsdorf AI, Battista V, Arbing R, Gordon PH, Mitsumoto H, Levin B, Thompson JL; QALS study group. Excellent inter-rater, intra-rater, and telephone-administered reliability of the ALSFRS-R in a multicenter clinical trial. Amyotroph Lateral Scler. 2007 Feb;8(1):42-6.</citation>
    <PMID>17364435</PMID>
  </reference>
  <reference>
    <citation>Cudkowicz M, Bozik ME, Ingersoll EW, Miller R, Mitsumoto H, Shefner J, Moore DH, Schoenfeld D, Mather JL, Archibald D, Sullivan M, Amburgey C, Moritz J, Gribkoff VK. The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis. Nat Med. 2011 Nov 20;17(12):1652-6. doi: 10.1038/nm.2579.</citation>
    <PMID>22101764</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>January 22, 2020</study_first_submitted>
  <study_first_submitted_qc>January 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 28, 2020</study_first_posted>
  <last_update_submitted>July 21, 2020</last_update_submitted>
  <last_update_submitted_qc>July 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antioxidants</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

